Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Jasper Therapeutics (Nasdaq:JSPR) announced that its board has begun a comprehensive review of strategic alternatives to maximize shareholder value after assessing current market conditions.
Options include asset sales or licenses, collaborations, a company sale, business combination or merger, or an orderly wind-down, while continuing cost-saving efforts and regulatory compliance.
Jasper Therapeutics (Nasdaq:JSPR) reported first quarter 2026 results and a briquilimab clinical update. The company focuses on mast cell driven diseases such as chronic spontaneous urticaria (CSU) and asthma.
Jasper refiled a Phase 2b CSU protocol with the FDA, highlighted positive briquilimab data, held $14.1 million in cash and cash equivalents, and reported a net loss of $1.2 million for Q1 2026.
Jasper Therapeutics (Nasdaq: JSPR) reported Q4 and full-year 2025 results and clinical updates on briquilimab, an anti‑c‑Kit antibody for chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. Key clinical signals: positive BEACON and open‑label extension CSU data, ETESIAN asthma proof‑of‑concept, dose selection for Phase 2b planned H2 2026. Financials: cash of $28.7M at Dec 31, 2025 and a 2025 net loss of $75.8M. Company noted Phase 2b enrollment timing is pending capital availability.
Jasper Therapeutics (Nasdaq: JSPR) announced management will present at the 46th Annual TD Cowen Healthcare Conference in Boston, March 2-4, 2026.
The company will participate in a Fireside Chat on Monday, March 2, 2026 at 3:50 PM ET. According to the company, a live webcast will be available on its investor website and an archived replay will remain online for 30 days.
Jasper Therapeutics (NASDAQ: JSPR) reported updated clinical data for briquilimab in chronic spontaneous urticaria (CSU) from the randomized BEACON Phase 1b/2a study and an open‑label extension. In the BEACON 240mg→180mg Q8W cohort (briquilimab, n=6) mean UAS7 fell by 31 points at 12 weeks; 83% had UAS7=0 by week 3 and 67% had UAS7=0 at week 12. In the open‑label extension, 58% of CSU patients (n=36) achieved UAS7=0 at 12 weeks and 75% reached UAS7≤6. Median follow‑up was 205 days in 63 patients. Safety findings were infrequent, predominantly low‑grade, and no dose‑limiting toxicities were observed. Jasper said data support dose selection for a Phase 2b CSU study planned for the second half of 2026.
Jasper Therapeutics (Nasdaq: JSPR) named Jeet Mahal as President and Chief Executive Officer and board member, effective Jan 5, 2026, with Thomas Wiggans appointed Executive Chairperson. Jasper is preparing to commence a registrational program for briquilimab in chronic spontaneous urticaria (CSU) and cited proof of concept in CSU, chronic inducible urticaria (CIndU) and asthma. The company will host an investor webinar on Jan 8, 2026 at 8:00 a.m. ET to present updated BEACON study and open-label extension data; slides and a webcast archive will be posted on investor relations.
Jasper Therapeutics (Nasdaq: JSPR) reported positive preliminary Phase 1b ETESIAN results for briquilimab in allergic asthma and closed an internal BEACON investigation. A single 180mg subcutaneous dose produced marked reductions in sputum eosinophils and serum tryptase and improved Early and Late Asthmatic Response (LAR %Max FEV1 +10.4% at 6 weeks, +8.7% at 12 weeks versus baseline). Briquilimab was well tolerated. The BEACON probe found no drug product issues; Jasper concluded the anomalous lack of CSU efficacy in 10 US patients likely reflected patient selection (9 of 10 likely not mast cell-driven). Jasper expects additional BEACON data in Q1 2026 and plans Phase 2b CSU dosing selection mid-2026.
Jasper Therapeutics (NASDAQ:JSPR) will host an investor webinar on Tuesday, December 2, 2025 at 8:00 am ET to present preliminary ETESIAN asthma data and findings from its investigation into anomalous BEACON CSU results reported in July. The session will include remarks from Jasper management and Dr. Martin Metz, M.D., lead EU investigator in BEACON, followed by a live Q&A. Registration is required and presentation slides plus live and archived webcast links will be posted on Jasper's Investor Relations Events page.
Jasper Therapeutics (Nasdaq: JSPR) reported Q3 2025 results and a corporate update on Nov 10, 2025. Key financials: $50.9M cash as of Sept 30, 2025 and a $30M underwritten offering that the company says extends cash runway through H1 2026. Q3 operating items included R&D $14.4M, G&A $4.8M, and a net loss $18.7M (loss per share $1.13).
Clinically, Jasper is investigating anomalous efficacy in two BEACON cohorts (240mg Q8W and 240mg/180mg Q8W) and reports preliminary findings that the anomalies do not appear related to drug substance or drug product. The company plans final investigation conclusions in Q4 2025, initial ETESIAN asthma data in Q4 2025, and additional BEACON/OLE updates in early Q1 2026, aiming to select dose and commence a Phase 2b CSU study mid-2026.
Jasper Therapeutics (Nasdaq: JSPR) announced management will present at four investor conferences in November–December 2025: UBS Global Healthcare (Nov 9–12), Stifel Healthcare (presentation Nov 11, 4:00 PM ET, presentation), TD Cowen Immunology & Inflammation (presentation Nov 12, 3:30 PM ET, fireside chat) and Evercore Healthcare (presentation Dec 3, 3:00 PM ET, fireside chat).
Live webcasts will be available on Jasper's Investor Relations "News & Events – Events" page and archived replays will be posted for 30 days after each live broadcast.